Carmot, Genentech in discovery deal

Carmot Therapeutics Inc. (San Francisco, Calif) and the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) partnered to use Carmot's Chemotype Evolution platform fragment-based lead discovery technology to identify novel drug candidates. Genentech will be responsible for development and commercialization of identified candidates. Carmot will receive an undisclosed upfront payment and is eligible for milestones and royalties. ...